替尔泊肽与甘精胰岛素对2型糖尿病患者肾脏结局的影响:SURPASS-4试验的事后分析
SURPASS-4试验的事后分析比较了替尔泊肽与甘精胰岛素对2型糖尿病伴高心血管风险患者肾脏参数的影响。结果显示,替尔泊肽组eGFR下降速率较甘精胰岛素组减慢(组间差异2.2 mL/min/1.73 m²/年),UACR降低,复合肾脏终点风险显著降低(HR 0.58)。
要点
- 替尔泊肽组eGFR年下降速率较甘精胰岛素组减慢2.2 mL/min/1.73 m²/年(95%CI 1.6-2.8)。
- 替尔泊肽组UACR较基线变化-6.8%,甘精胰岛素组增加36.9%,组间差异-31.9%。
- 替尔泊肽组复合肾脏终点发生风险显著低于甘精胰岛素组(HR 0.58,95%CI 0.43-0.80)。
核心结论
- 在2型糖尿病伴高心血管风险人群中,替尔泊肽较甘精胰岛素以具有临床意义的方式减缓eGFR下降速率并降低UACR。
研究设计与样本
- SURPASS-4试验的事后分析,该试验为随机、开放标签、平行组、3期研究,在14个国家187个中心进行。
- 纳入年龄≥18岁、接受二甲双胍/磺脲类/SGLT2抑制剂治疗、基线HbA1c 7.5-10.5%、BMI≥25 kg/m²、确诊心血管疾病或高心血管事件风险的2型糖尿病患者。
- 随机分配比例为1:1:1:3至替尔泊肽5 mg、10 mg、15 mg每周一次皮下注射或甘精胰岛素每日一次皮下注射。
- 治疗最长104周,中位治疗持续时间85周;改良意向治疗人群比较替尔泊肽合并组与甘精胰岛素组的eGFR下降速率和UACR。
主要发现
- 基线平均eGFR为81.3 mL/min/1.73 m²(SD 21.11),中位UACR为15.0 mg/g(IQR 5.0-55.8)。
- 替尔泊肽合并组eGFR平均年下降速率为-1.4 mL/min/1.73 m²/年(SE 0.2),甘精胰岛素组为-3.6 mL/min/1.73 m²/年(SE 0.2),组间差异2.2(95%CI 1.6-2.8)。
- eGFR<60 mL/min/1.73 m²者中替尔泊肽减缓eGFR下降的幅度较eGFR≥60 mL/min/1.73 m²者更明显(组间差异3.7,95%CI 2.4-5.1)。
- 甘精胰岛素组UACR从基线至随访增加36.9%(95%CI 26.0-48.7),替尔泊肽组变化-6.8%(95%CI -14.1至1.1),组间差异-31.9%(95%CI -37.7至-25.7)。
- 替尔泊肽组复合肾脏终点发生风险显著低于甘精胰岛素组(HR 0.58,95%CI 0.43-0.80)。
临床怎么用
- 作者认为,在2型糖尿病伴高心血管风险人群中,替尔泊肽较甘精胰岛素可减缓eGFR下降并降低UACR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA1c concentrations, bodyweight, and blood pressure more than titrated daily insulin glargine in people with type 2 diabetes inadequately controlled on oral diabetes treatments and with high cardiovascular risk. We aimed to compare the effects of tirzepatide and insulin glargine on kidney parameters and outcomes in people with type 2 diabetes. METHODS: We did a post-hoc analysis of data from SURPASS-4, a randomised, open-label, parallel-group, phase 3 study at 187 sites (including private practice, research institutes, and hospitals) in 14 countries. Eligible participants were adults (age ≥18 years), with type 2 diabetes treated with any combination of metformin, sulfonylurea, or SGLT2 inhibitor, and with baseline HbA1c of 7·5-10·5% (58-91 mmol/mol), BMI of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Randomisation via an interactive web-response system was 1:1:1:3 to a once-weekly subcutaneous injection of tirzepatide (5 mg, 10 mg, or 15 mg) or a once-daily subcutaneous injection of titrated insulin glargine (100 U/mL). The study included up to 104 weeks of treatment, with a median treatment duration of 85 weeks. We compared the rates of estimated glomerular filtration rate (eGFR) decline and the urine albumin-creatinine ratio (UACR) between the combined tirzepatide groups and the insulin glargine group in the modified intention-to-treat population. The kidney composite outcome was time to first occurrence of eGFR decline of at least 40% from baseline, end-stage kidney disease, death owing to kidney failure, or new-onset macroalbuminuria. This study is registered with ClinicalTrials.gov, NCT03730662. FINDINGS: Between Nov 20, 2018, and Dec 30, 2019, we screened 3045 people, of whom 1043 (34%) were ineligible, and 2002 (66%) were randomly assigned to a study drug (997 to tirzepatide and 1005 to insulin glargine). 1995 (>99%) of 2002 received at least one dose of tirzepatide (n=995) or insulin glargine (n=1000). At baseline, participants had a mean eGFR of 81·3 (SD 21·11) mL/min per 1·73 m2 and a median UACR of 15·0 mg/g (IQR 5·0-55·8). The mean rate of eGFR decline was -1·4 (SE 0·2) mL/min per 1·73 m2 per year in the combined tirzepatide groups and -3·6 (0·2) mL/min per 1·73 m2 per year in the insulin group (between-group difference 2·2 [95% CI 1·6 to 2·8]). Compared with insulin glargine, the reduction in the annual rate of eGFR decline induced by tirzepatide was more pronounced in participants with eGFR less than 60 mL/min per 1·73 m2 than in those with eGFR 60 mL/min per 1·73 m2 or higher (between-group difference 3·7 [95% CI 2·4 to 5·1]). UACR increased from baseline to follow-up with insulin glargine (36·9% [95% CI 26·0 to 48·7]) but not with tirzepatide (-6·8% [-14·1 to 1·1]; between-group difference -31·9% [-37·7 to -25·7]). Participants who received tirzepatide showed a significantly lower occurrence of the composite kidney endpoint compared with those who received insulin glargine (hazard ratio 0·58 [95% CI 0·43 to 0·80]). INTERPRETATION: Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine. FUNDING: Eli Lilly and Company.
引用
- Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. doi:10.1016/S2213-8587(22)00243-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。